Germ line DDX41 mutations define a unique subtype of myeloid neoplasms
Blood · 2023
DOI: 10.1182/blood.2022018221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Hideki Makishima und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders. Die Arbeit wurde bisher 156-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features of DDX41-mutated MNs remain to be elucidated. Here we performed a comprehensive characterization of DDX41-mutated MNs, enrolling a total of 346 patients with DDX41 pathogenic/likely-pathogenic (P/LP) germ line variants and/or somatic mutations from 9082 MN patients, together with 525 first-degree relatives of DDX41-mutated and wild-type (WT) patients. P/LP DDX41 germ line variants explained ∼80% of known germ line predisposition to MNs in adults. These risk variants were 10-fold more enriched in Japanese MN cases (n = 4461) compared with the general population of Japan (n = 20 238). This enrichment of DDX41 risk alleles was much more prominent in male than female (20.7 vs 5.0). P/LP DDX41 variants conferred a large risk of developing MNs, which was negligible until 40 years of age but rapidly increased to 49% by 90 years of age. Patients with myelodysplastic syndromes (MDS) along with a DDX41-mutation rapidly progressed to acute myeloid leukemia (AML), which was however, confined to those having truncating variants. Comutation patterns at diagnosis and at progression to AML were substantially different between DDX41-mutated and WT cases, in which none of the comutations affected clinical outcomes. Even TP53 mutations made no exceptions and their dismal effect, including multihit allelic status, on survival was almost completely mitigated by the presence of DDX41 mutations. Finally, outcomes were not affected by the conventional risk stratifications including the revised/molecular International Prognostic Scoring System. Our findings establish that MDS with DDX41-mutation defines a unique subtype of MNs that is distinct from other MNs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
- Departments of Medicine and Human Genetics, Section of Hematology/Oncology, The University of Chicago, Chicago, IL.
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
- Department of Biomedicine and Prevention, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy.
- Laboratory for Genotyping Development, Center for Integrative Medical Sciences (IMS), RIKEN, Yokohama, Japan.
- King's College Hospital NHS Foundation Trust, and King's College London, London, United Kingdom.
ORCID-Profile: Hideki Makishima, Sophia Korotev, Carmelo Gurnari, Nobuyuki Kakiuchi, Hiroko Tanaka, Yotaro Ochi, Masahiro M Nakagawa, Rurika Okuda, Shigeru Chiba, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Fumihiko Matsuda, Chantana Polprasert, Luca Malcovati, Michiaki Kubo
Zitieren
APA
Makishima, H., Saiki, R., Nannya, Y., Korotev, S., Gurnari, C., Takeda, J., Momozawa, Y., Best, S., Krishnamurthy, P., Yoshizato, T., Atsuta, Y., Shiozawa, Y., Iijima-Yamashita, Y., Yoshida, K., Shiraishi, Y., Nagata, Y., Kakiuchi, N., Onizuka, M., Chiba, K., …, & Ogawa, S. (2023). Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. https://doi.org/10.1182/blood.2022018221
Vancouver
Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023. doi:10.1182/blood.2022018221
BibTeX
@article{Makishima2023,
author = {Makishima, Hideki and Saiki, Ryunosuke and Nannya, Yasuhito and Korotev, Sophia and Gurnari, Carmelo and Takeda, June and Momozawa, Yukihide and Best, Steve and Krishnamurthy, Pramila and Yoshizato, Tetsuichi and Atsuta, Yoshiko and Shiozawa, Yusuke and Iijima-Yamashita, Yuka and Yoshida, Kenichi and Shiraishi, Yuichi and Nagata, Yasunobu and Kakiuchi, Nobuyuki and Onizuka, Makoto and Chiba, Kenichi and Tanaka, Hiroko and Kon, Ayana and Ochi, Yotaro and Nakagawa, Masahiro M and Okuda, Rurika and Mori, Takuto and Yoda, Akinori and Itonaga, Hidehiro and Miyazaki, Yasushi and Sanada, Masashi and Ishikawa, Takayuki and Chiba, Shigeru and Tsurumi, Hisashi and Kasahara, Senji and Müller-Tidow, Carsten and Takaori-Kondo, Akifumi and Ohyashiki, Kazuma and Kiguchi, Toru and Matsuda, Fumihiko and Jansen, Joop H and Polprasert, Chantana and Blombery, Piers and Kamatani, Yoichiro and Miyano, Satoru and Malcovati, Luca and Haferlach, Torsten and Kubo, Michiaki and Cazzola, Mario and Kulasekararaj, Austin G and Godley, Lucy A and Maciejewski, Jaroslaw P and Ogawa, Seishi},
title = {Germ line DDX41 mutations define a unique subtype of myeloid neoplasms},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022018221}
}
EUVIMED